Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 2
2008 5
2009 6
2010 2
2011 1
2012 1
2013 3
2014 4
2015 7
2016 5
2017 6
2018 13
2019 15
2020 9
2021 16
2022 25
2023 15
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. Among authors: cescon dw. Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9. Lancet. 2020. PMID: 33278935 Clinical Trial.
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. Among authors: cescon dw. N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. N Engl J Med. 2022. PMID: 35857659 Clinical Trial.
Circulating tumor DNA and liquid biopsy in oncology.
Cescon DW, Bratman SV, Chan SM, Siu LL. Cescon DW, et al. Nat Cancer. 2020 Mar;1(3):276-290. doi: 10.1038/s43018-020-0043-5. Epub 2020 Mar 20. Nat Cancer. 2020. PMID: 35122035 Review.
CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma.
Chan CY, Chiu DK, Yuen VW, Law CT, Wong BP, Thu KL, Cescon DW, Soria-Bretones I, Cheu JW, Lee D, Tse AP, Zhang MS, Tan KV, Ng IO, Khong PL, Yau TC, Bray MR, Mak TW, Wong CC. Chan CY, et al. Among authors: cescon dw. Proc Natl Acad Sci U S A. 2022 Aug 9;119(32):e2119514119. doi: 10.1073/pnas.2119514119. Epub 2022 Aug 1. Proc Natl Acad Sci U S A. 2022. PMID: 35914158 Free PMC article.
PRMT inhibition induces a viral mimicry response in triple-negative breast cancer.
Wu Q, Nie DY, Ba-Alawi W, Ji Y, Zhang Z, Cruickshank J, Haight J, Ciamponi FE, Chen J, Duan S, Shen Y, Liu J, Marhon SA, Mehdipour P, Szewczyk MM, Dogan-Artun N, Chen W, Zhang LX, Deblois G, Prinos P, Massirer KB, Barsyte-Lovejoy D, Jin J, De Carvalho DD, Haibe-Kains B, Wang X, Cescon DW, Lupien M, Arrowsmith CH. Wu Q, et al. Among authors: cescon dw. Nat Chem Biol. 2022 Aug;18(8):821-830. doi: 10.1038/s41589-022-01024-4. Epub 2022 May 16. Nat Chem Biol. 2022. PMID: 35578032 Free PMC article.
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer.
Wu Q, Ba-Alawi W, Deblois G, Cruickshank J, Duan S, Lima-Fernandes E, Haight J, Tonekaboni SAM, Fortier AM, Kuasne H, McKee TD, Mahmoud H, Kushida M, Cameron S, Dogan-Artun N, Chen W, Nie Y, Zhang LX, Vellanki RN, Zhou S, Prinos P, Wouters BG, Dirks PB, Done SJ, Park M, Cescon DW, Haibe-Kains B, Lupien M, Arrowsmith CH. Wu Q, et al. Among authors: cescon dw. Nat Commun. 2020 Aug 21;11(1):4205. doi: 10.1038/s41467-020-18020-8. Nat Commun. 2020. PMID: 32826891 Free PMC article.
Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer.
Langille E, Al-Zahrani KN, Ma Z, Liang M, Uuskula-Reimand L, Espin R, Teng K, Malik A, Bergholtz H, Ghamrasni SE, Afiuni-Zadeh S, Tsai R, Alvi S, Elia A, Lü Y, Oh RH, Kozma KJ, Trcka D, Narimatsu M, Liu JC, Nguyen T, Barutcu S, Loganathan SK, Bremner R, Bader GD, Egan SE, Cescon DW, Sørlie T, Wrana JL, Jackson HW, Wilson MD, Witkiewicz AK, Knudsen ES, Pujana MA, Wahl GM, Schramek D. Langille E, et al. Among authors: cescon dw. Cancer Discov. 2022 Dec 2;12(12):2930-2953. doi: 10.1158/2159-8290.CD-21-0865. Cancer Discov. 2022. PMID: 36108220 Free PMC article.
Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.
Chan CY, Yuen VW, Chiu DK, Goh CC, Thu KL, Cescon DW, Soria-Bretones I, Law CT, Cheu JW, Lee D, Tse AP, Tan KV, Zhang MS, Wong BP, Wong CM, Khong PL, Ng IO, Bray MR, Mak TW, Yau TC, Wong CC. Chan CY, et al. Among authors: cescon dw. Hepatology. 2023 Mar 1;77(3):729-744. doi: 10.1002/hep.32461. Epub 2023 Feb 17. Hepatology. 2023. PMID: 35302667
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J. Adams S, et al. Among authors: cescon dw. Ann Oncol. 2019 Mar 1;30(3):397-404. doi: 10.1093/annonc/mdy517. Ann Oncol. 2019. PMID: 30475950 Free article. Clinical Trial.
131 results